Advances in molecular profiling have significantly improved our understanding of CRC biology, with mutations in the RAS gene family—particularly V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and neuroblastoma RAS viral oncogene homolog (NRAS)—emerging as key biomarkers for guiding therapeutic decisions in metastatic CRC (mCRC) [4,5]. The gene discussed is NRAS; the disease is colorectal carcinoma.